People Background Check
Find People:

Benjamin S Szwergold, Age 7860 E Linden Ave UNIT 6B, Englewood, NJ 07631

Get Report
Known as:
Ben S Szwergold Benj Szwergold Benjamin D
Related to:
Joseph F Doyle 86

Benjamin Szwergold Phones & Addresses

Englewood, NJ

26 Pleasant St, West Lebanon, NH 03784 (603) 298-9797

26 Pleasant St UNIT 29, West Lebanon, NH 03784 (603) 790-8295

29 Village Grn, West Lebanon, NH 03784 (603) 298-9797

Lebanon, NH

Cedarhurst, NY

Teaneck, NJ

Brooklyn, NY

Philadelphia, PA

Hanover, NH

26 Pleasant St, West Lebanon, NH 03784

Show more

Work

Position: Professional/Technical

Education

Degree: Graduate or professional degree

Mentions for Benjamin S Szwergold

Benjamin Szwergold resumes & CV records

Resumes

Benjamin Szwergold Photo 8

Chief Strategy Officer

Location:
26 Pleasant St, West Lebanon, NH 03784
Industry:
Biotechnology
Work:
Seroclear
Chief Strategy Officer Dartmouth College Sep 1997 - Aug 2007
Research Associate Professor Fox Chase Cancer Center Sep 1984 - Aug 1997
Research Associate
Education:
Columbia University Graduate School of Arts and Sciences 1979 - 1984
Doctorates, Doctor of Philosophy Kibbutz Yagur Hs
A. Lincoln Hs, Brooklyn
Columbia University
Skills:
Teaching, Physics, Biochemistry, Science, Biology, Physical Sciences, Chemistry
Languages:
English
Polish
Hebrew
Yiddish
Russian
Benjamin Szwergold Photo 9

Independent Health, Wellness And Fitness Professional

Location:
Groraum New York City und Umgebung
Industry:
Gesundheit, Wellness & Fitness

Publications & IP owners

Us Patents

Treatment For Complications Of Type 2 Diabetes

US Patent:
6498193, Dec 24, 2002
Filed:
Dec 13, 2000
Appl. No.:
09/735683
Inventors:
Paul J. Beisswenger - Hanover NH
Benjamin S. Szwergold - Hanover NH
Assignee:
Trustees of Dartmouth College - Hanover NH
International Classification:
A61K 31155
US Classification:
514635
Abstract:
A method is disclosed of lowering plasma levels of -dicarbonyl precursors of advanced glycation end-products, such as methylglyoxal, in a patient having type 2 diabetes by administrating metformin in a dosage from twenty-five to fifty percent in excess of its antidiabetic therapeutic regimen. The high dosage of metformin acts to reduce plasma levels of -dicarbonyl compounds by a mechanism distinct from that whereby it exerts its antidiabetic activity.

Method For Inhibiting Or Reversing Non-Enzymatic Glycation

US Patent:
8138227, Mar 20, 2012
Filed:
Jun 1, 2007
Appl. No.:
11/756689
Inventors:
Benjamin Szwergold - West Lebanon NH, US
Assignee:
Trustees of Dartmouth College - Hanover NH
International Classification:
A61K 31/13
US Classification:
514665, 514866
Abstract:
The present invention relates to a method for inhibiting or reversing non-enzymatic glycation of the first intermediate of a biological moiety using an α-thiolamine. By inhibiting or reversing non-enzymatic glycation of the biological moiety, conditions such as aging and diabetic complications can be prevented or reversed.

Possible Relatives

Benjamin B Joiner  Benjamin J Stanton  Benjamin O Staples  Benjamin C Stapleton  Benjamin A Stark  Benjamin R Stauffer  Benjamin P Mcgovern  Benjamin R Mcgrath  Benjamin J Stein  Benjamin W Mcgregor 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.